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Abstract
DNA damage and replication checkpoints mediated by the ATR-CHEK1 pathway are key to the maintenance of
genome stability, and both ATR and CHEK1 have been proposed as potential breast cancer susceptibility genes.
Many novel variants recently identified by the large resequencing projects have not yet been thoroughly tested in
genome-wide association studies for breast cancer susceptibility. We therefore used a tagging SNP (tagSNP)
approach based on recent SNP data available from the 1000 genomes projects, to investigate the roles of ATR and
CHEK1 in breast cancer risk and survival. ATR and CHEK1 tagSNPs were genotyped in the Sheffield Breast Cancer
Study (SBCS; 1011 cases and 1024 controls) using Illumina GoldenGate assays. Untyped SNPs were imputed using
IMPUTE2, and associations between genotype and breast cancer risk and survival were evaluated using logistic and
Cox proportional hazard regression models respectively on a per allele basis. Significant associations were further
examined in a meta-analysis of published data or confirmed in the Utah Breast Cancer Study (UBCS). The most
significant associations for breast cancer risk in SBCS came from rs6805118 in ATR (p=7.6x10-5) and rs2155388 in
CHEK1 (p=3.1x10-6), but neither remained significant after meta-analysis with other studies. However, meta-analysis
of published data revealed a weak association between the ATR SNP rs1802904 (minor allele frequency is 12%) and
breast cancer risk, with a summary odds ratio (confidence interval) of 0.90 (0.83-0.98) [p=0.0185] for the minor allele.
Further replication of this SNP in larger studies is warranted since it is located in the target region of 2 microRNAs.
No evidence of any survival effects of ATR or CHEK1 SNPs were identified. We conclude that common alleles of
ATR and CHEK1 are not implicated in breast cancer risk or survival, but we cannot exclude effects of rare alleles and
of common alleles with very small effect sizes.
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Introduction
Despite the successes of the genome-wide association
studies (GWAS) in identifying breast cancer susceptibility loci,
the level of breast cancer risk explained by these susceptibility
loci remains modest [1]. Good coverage of genetic markers,
usually single nucleotide polymorphisms (SNPs) that
sufficiently represent the surrounding variants through linkage
disequilibrium (LD), is essential to a successful screening of
susceptibility loci. So far, not all regions have been well
captured, and more genetic markers may be needed. For
example, novel disease susceptibility loci have been identified
from the meta-analysis of several GWAS together [2,3],
suggesting that some loci are not well captured in the initial
GWAS discovery stage, partly due to a lack of power. The
1000 genomes project is a good resource to complement the
incomplete coverage of GWAS chips, in which low coverage
whole-genome shotgun sequencing and targeted sequencing
of known exons has been carried out on a large number of
samples [4]. Many of the resulting novel variants have not yet
been thoroughly tested in GWAS.
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The ATR-CHEK1 DNA damage response pathway is key for
maintenance of genome stability. ATR recognises DNA single-
strand breaks, and activates CHEK1 to initiate cell cycle arrest
and DNA replication inhibition, the repression of cyclin proteins,
and the activation of Fanconi Anemia proteins for DNA repair
[5]. The close cross-talk between CHEK1 and BRCA1, the
breast cancer tumour suppressor gene, at the G2/M checkpoint
[6] suggests the potential importance of this pathway in breast
cancer.
To date, a small number of gene-based association studies
have been carried out to investigate the roles of ATR and
CHEK1 as breast cancer susceptibility genes, using a tagging
SNP (tagSNPs) approach. In these studies a subset of
representative SNPs were chosen from previous reference
panels that are less complete than those currently available
[7–12]. Inconclusive evidence was reported for the ATR and
CHEK1 SNPs in association with breast cancer risk [7–12]. In
addition, associations with survival following breast cancer
diagnosis are examined in two of these studies, and null
findings were reported [8,12]. Here, we have carried out a more
detailed study of the role of the ATR and CHEK1 in breast
cancer risk and survival based on the more complete resources
now available from the 1000 genomes project.
Materials and Methods
Ethics Statement
All Sheffield and Utah participants gave written informed
consent for the collection of data and blood samples. The
Sheffield and Utah studies were approved by South Sheffield
Research Ethics Committee and University of Utah Institutional
Review Board, respectively.
Study populations
The Sheffield Breast Cancer Study (SBCS) recruited
histologically confirmed breast cancer patients from surgical
outpatient clinics in the Royal Hallamshire Hospital, Sheffield
and Rotherham District Hospital from 1998 to 2005. Women
aged 50-60 years attending the mammography breast
screening service in Sheffield between October 2000 and
January 2004 were drawn as control subjects if there was no
evidence of breast lesions in their mammograms. Samples
from 1011 cases and 1024 controls were available for
genotyping. Cases and controls were all resident in the
Sheffield area and of northern European ancestry. Information
regarding histology, grade, lymph node status, and tumour size
was obtained from the medical records and histopathology
reports. Vital status was updated as of September 2009 by
linking hospital records and the Trent Cancer Registry [13,14].
The Utah Breast Cancer Study (UBCS) identified breast
cancer patients from high risk cancer pedigrees, identified
through the Utah Population database linked to the Utah
Cancer Registry, and excluded cancer patients having BRCA1
or BRCA2 mutations. Control subjects comprised distantly
related and unrelated cancer-free individuals matched on sex,
birth year (within 5 years) and birthplace [15]. The UBCS
comprised 898 breast cases and 899 controls.
TagSNP selection
TagSNPs were selected from the common SNPs [minor
allele frequency (MAF) ≧2%] identified from the whole-genome
sequencing of 60 unrelated individuals of European ancestry in
Utah (CEU low-coverage pilot, 2010-07 release) from the 1000
genomes project [4]. SNPs with Illumina GoldenGate assay
design scores of ≧0.8 were given priority as tagSNPs if they
were genotyped in the previously reported studies [7–9]. Also,
priority was given to SNPs in microRNA target sites as
predicted by MicroRNA.org (2010-08 release) [16], since
microRNA target SNPs have been shown to affect gene
expression by the disruption of the interaction between
microRNA and its target mRNA [17]. Aggressive 2-3 marker
tagging at r2 ≧ 0.8 was used to select tagSNPs based on the
hg19 genomic intervals on chromosome
3:142118077-142347668 and chromosome 11:
125445035-125596150 containing the ATR and CHEK1 genes
respectively, plus 50kb upstream and downstream of each
gene, by use of the Haploview 4.1 software [18]. The initial
tagSNP set (32 ATR and 40 CHEK1 tagSNPs) was further
supplemented with tags for the known common variants in the
exon targeted capture sequencing data on 90 CEU and 43
British from England and Scotland (GBR) from the 1000
genomes project (exon pilot; 2010-03 release) [4]. An
additional 8 ATR and 10 CHEK1 tagSNPs were thus identified,
resulting in a total of 40 ATR and 50 CHEK1 SNPs for
genotyping. The details of the source of tagSNPs and priority
(publications or microRNA target sites) are given in Table S1 in
File S1.
Genotyping & quality control
Genotyping was carried out in 96-well microtiter plates using
custom Illumina GoldenGate VeraCode assays on the Illumina
BeadXpress platform. Genotypes were determined by the
genotyping module (1.94) of the Illumina GenomeStudio suite
(version 2011.1). Genotyping quality was examined by SNP
call rate, duplicate concordance and the Hardy-Weinberg
equilibrium (HWE) test in controls. Eight ATR and 6 CHEK1
tagSNPs were excluded from the analysis having call rates of
<90%, duplicate concordance of <98%, HWE p value of < 10-3
or monomorphism (Table S2 in File S1). Further to this,
samples called on < 80% of SNPs were also excluded. The
final SBCS data consisted of 32 ATR and 44 CHEK1 tagSNPs
on 955 cases and 955 controls. The selected tagSNPs capture
74.9% of ATR and 71.7% of CHK1 SNPs at r2 of ≧ 0.9, with
mean r2 of 88% and 87.4% respectively for SNPs with minor
allele frequencies at least 0.02, based on the 1000 genomes
2011-05 release.
Statistical analysis
Imputation.  Missing genotypes were imputed for typed
SNPs and untyped variants using Impute2 [19,20] based on the
1000 genomes phase I reference panel with singleton variants
filtered out. Variants with European MAF ≧ 2% within the ATR
and CHEK1 regions were imputed, and included in the
subsequent analysis if their imputation information score was
greater than 0.8. After filtering, the numbers of eligible imputed
variants were 454 and 434 for the ATR and CHEK1 regions,
respectively.
ATR and CHEK1 SNPs with Breast Cancer
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Breast cancer risk .  Allelic dosage for the minor allele was
calculated for typed SNPs and imputed variants, to take
account of imputation uncertainty, and was included in a
logistic regression model for each SNP. To screen for
association with breast cancer risk, allelic odds ratio (OR), 95%
confidence interval (CI) and Wald p values were calculated for
each SNP using the logistic regression model.
Meta analysis .  A literature search was conducted using
HuGE Navigator [21]. The terms “ATR or CHEK1” were used,
and the resulting publications were limited to breast neoplasms
and gene candidate studies on Europeans. Meta-analysis was
then carried out for the published SNPs that were also
genotyped in our study. We also included data from a genome-
wide association study based on postmenopausal women in
Nurses’ Health Study (Cancer Genetic Markers of
Susceptibility, CGEMS) [22] if data on relevant SNPs were
available. Study specific ORs were pooled by means of both
fixed and random models, and the homogeneity of ORs across
the centres was evaluated by both Cochran’s Q test and I2
measurement implemented in the R metafor package [23].
Breast cancer survival .  The Cox proportional hazard
model, including age at diagnosis and the left-censoring time
between study entry and diagnosis, was employed to estimate
the hazard ratio (HR) and 95% CI for each SNP for breast
cancer survival. Further adjustment was carried out for lymph
node status (binary variable; negative, positive), grade
(categorical variable; 1, 2, 3), and tumour size (categorical
variable; <2, 2-5, >5 cm) for any significant SNPs. All reported
p values are nominal and two-sided. All statistical tests were
performed using R 2.15.2.
Results
Breast cancer risk
There are a total of 486 SNPs (32 typed SNPs and 454
imputed variants) in the ATR region (229.5 kb) which also
contains the XRN1 and PLS1 genes. Of these variants, the
typed ATR SNP rs6805118 yielded the most significant signal
for breast cancer risk, with p value of 7.6x10-5 (Figure 1). The
Figure 1.  Association plots of the 32 typed SNPs and 454 imputed variants in the ATR region.  The most significant signal
(rs6805118, p=7.6x10-5) is labelled with the large blue circle. Circle symbols stand for the typed SNPs and diamond symbols
represent the imputed variants. LD associations (r2) with rs6805118 were calculated in 85 CEU and 89 GBR (integrated call release
as of 2010-11-23) in the 1000 genomes project. Gene transcripts are indicated by the dark green lines, with right arrowhead for the
“+” strand and left arrowhead for the “-” strand. Recombination rate (blue line) was obtained from HapMap II.
doi: 10.1371/journal.pone.0068578.g001
ATR and CHEK1 SNPs with Breast Cancer
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minor allele of rs6805118 was protective for breast cancer with
OR (95% CI) of 0.66 (0.54-0.81) (Table S3 in File S1). The
imputed SNP rs2227932, a synonymous ATR SNP, in LD with
rs6805118 with r2 of 0.98 demonstrated a similar protective
effect [0.75 (0.61-0.93), p=8.3x10-3] (Figure 1 and Table S3 in
File S1).
For the chromosome 11: 125445035-125596150 region
containing the EI24, STT3A, CHEK1 and ACRV1 genes, the
most significant association came from the typed rs2155388
SNP at p value of 3.1x10-6 (Figure 2), with an allelic effect of
OR of 1.43 (95% CI: 1.23-1.65) (Table S4 in File S1). This SNP
mapped to the etoposide induced 2.4 (EI24) gene. The EI24
protein is involved in p53-mediated apoptosis. There were
some other nominally significant associations in the intergenic
region telomeric to the ACRV1 gene (all p ≥5.6x10-4).
The top hits in each of the ATR and CHEK1 regions were
examined further. The ATR SNP rs6805118 was also
genotyped in the SEARCH [8] and NHS [9] studies. We
therefore conducted a meta-analysis to combine these data
and the results are shown in Figure 3A. We found evidence of
heterogeneity among the studies (phet<1x10-3; I2=86%). The
rs6805118 effect disappeared when all study-specific estimates
were combined, with a pooled OR (95% CI) of 0.83 (0.59-1.16)
under the random effect model [p=0.277].
The EI24 SNP rs2155388 in the CHEK1 region has not been
examined in published data. We therefore carried out further
genotyping in UBCS, and genotypes were successfully
obtained from 859 breast cases and 865 controls. However,
the result was not replicated in the UBCS data, with minor
allele OR (95% CI) of 1.01 (0.87, 1.17) (Figure 3B). Evidence
of heterogeneity between studies was found (phet=0.0014,
I2=90%), and the pooled OR (95% CI) was 1.20 (0.86-1.68)
[p=0.29] under the random effect model when both data were
combined.
We also carried out a meta-analysis in an effort to increase
power to identify any SNPs with small effects. Published data
are available for 11 ATR and 11 CHEK1 SNPs. There was no
evidence for effects on breast cancer risk for the majority of
Figure 2.  Association plots of the 44 typed SNPs and 434 imputed variants in the CHEK1 region.  The most significant signal
(rs2155388, p=3.1x10-5) is labelled with the large blue circle. The typed SNPs and the imputed variants are shown in the circle and
diamond symbols, respectively. Pair-wise r2 with rs2155388 were calculated in 85 CEU and 89 GBR (integrated call release as of
2010-11-23) in the 1000 genomes project. Gene transcripts are indicated by the dark green lines, with right arrowhead for the “+”
strand and left arrowhead for the “-” strand. Recombination rate (blue line) was obtained from HapMap II.
doi: 10.1371/journal.pone.0068578.g002
ATR and CHEK1 SNPs with Breast Cancer
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Figure 3.  Forest plots of the most significant ATR and CHEK1 SNP associations.  (A) the ATR rs6805118 associations.
SEARCH: Studies of Epidemiology and Risk Factors in Cancer Heredity [8]; NHS II: Nurses’ Health Study (premenopausal women)
[9]; SBCS: Sheffield Breast Cancer Study (B) the CHEK1 rs2155388 associations. UBCS: Utah Breast Cancer Study. For each
panel, fixed effect estimate (pooled OR) is shown, with p value for homogeneity (the Cochran’s Q test, phet) and I-squared for the
amount of heterogeneity in parenthesis. DL pooled OR stands for the random effect model derived from the DerSimonian-Laird
estimator.
doi: 10.1371/journal.pone.0068578.g003
ATR and CHEK1 SNPs with Breast Cancer
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Figure 4.  Meta-analysis of the association of rs1802904 (ATR region) with breast cancer risk.  Fixed effect estimate (pooled
OR) is shown, with p value for homogeneity (the Cochran’s Q test, phet) and I-squared for the amount of heterogeneity in
parenthesis. DL pooled OR stands for the random effect model derived from the DerSimonian-Laird estimator. MEC: Multiethnic
Cohort Study [7]; SEARCH: Studies of Epidemiology and Risk Factors in Cancer Heredity [8]; NHS II: Nurses’ Health Study
(postmenopausal women) [22]; SBCS: Sheffield Breast Cancer Study.
doi: 10.1371/journal.pone.0068578.g004
ATR and CHEK1 SNPs with Breast Cancer
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these, with all ORs close to unity (Figure S1 for the ATR SNPs;
Figure S2 for the CHEK1 SNPs), with the exception of the ATR
SNP rs1802904 (Figure 4). All studies, including SBCS,
showed that the minor allele of rs1802904 was consistently
protective for breast cancer by 8-22%, although this
association was not statistically significant in any individual
study. Study-specific ORs were homogenous for rs1802904
(phet=0.719, I2=0%), and the pooled OR were the same in both
fixed and random effect models, with OR (95% CI) of 0.90
(0.83-0.98) [p=0.0185].
Breast cancer survival
Vital status post-diagnosis was available for 923 of the 955
SBCS breast cancer subjects. There were 216 deaths during a
median of 10.44 years of follow up. Seventy-five percent of the
cases are prevalent cases, with a median of 2.32 years
between diagnosis and recruitment to study (data not shown).
Statistical evidence of survival association was only found for
the typed ATR SNP rs11920625 (Table S5 in File S1). The HR
(95% CI) was 1.37 (1.03-1.81) [p=0.0297] for the minor allele
after adjustment for age at diagnosis and accounting for the
left-censoring time. This association was no longer significant
after further adjusting for lymph node involvement, grade and
tumour size (p=0.064, Table S5 in File S1), and showed a
pooled HR (95% CI) of 1.18 (0.91-1.55) [p=0.21; data not
shown] when combining with a HR of 1.04 from the SEARCH
study [8]. There was no evidence of association between SNPs
in the CHEK1 region and breast cancer overall survival (Table
S6 in File S1).
Discussion
ATR in risk and survival
We identified an association between ATR rs6805118 and
breast cancer risk in the SBCS discovery set. A protective
effect of the minor allele of rs6805118 was also found in the
NHS premenopausal women [9], however the minor allele
conferred an increased risk of breast cancer in SEARCH
subjects [8]. Meta-analysis of these 3 datasets revealed a high
degree of heterogeneity and non-significant pooled OR,
suggesting little overall evidence for association with breast
cancer risk. In addition, neither SEARCH nor the current study
found any evidence for the association of this SNP with survival
[8].
The ATR synonymous rs1802904 SNP was found to be
nominally significantly associated with breast cancer risk
(p=0.0185) by means of the meta-analysis of the MEC
European Americans [7], NHS postmenopausal women [22],
SEARCH [8] and SBCS data. There was no evidence for
heterogeneity (I2=0). This SNP lies in the target region of hsa-
miR-27a and hsa-miR-27b [16], and in regions of histone
modification marks (H3k4me3 and H3k27ac). Therefore, this
SNP might exert its effect on breast cancer susceptibility via
transcriptional or post-transcriptional gene regulation. Although
we cannot rule out the possibility that this is a false positive,
further replication is warranted in a larger study.
CHEK1 region in risk and survival
The chromosome 11 interval containing the EI24 and CHEK1
genes is a frequently altered region in breast cancer. A
molecular study of breast cancer tumour samples revealed a
high frequency of deletions and promoter methylations in the
EI24 and CHEK1 genes, and reported poor survival
associations for patients with these alterations [24]. These
findings highlight the important roles of acquired deletions and
inherited epigenetic events of the EI24 and CHEK1 genes in
breast cancer progression. The SBCS finding of an rs2155388
effect was not replicated in the UBCS, despite that fact that
UBCS had an adequate power of 90% to detect similar
associations. Null results were also obtained in our survival
analysis. As a result, there was little evidence in our study
supporting any inherited sequence variants in the CHEK1
region being associated with breast cancer risk or survival.
In this study, while we can rule out moderate effects of the
less common/rare alleles, we are unable to exclude weaker
effects of these, for example, odds ratios of less than 1.46 for
SNPs with MAF of 5% or less, at 80% power. However, we
conclude there is little evidence to support any role for common
SNPs in the ATR and CHEK1 regions in breast cancer risk or
survival.
Supporting Information
Figure S1.  Meta-analysis of the typed SNPs in the ATR
region. .  For each panel, fixed effect estimate (pooled OR) is
shown, with p value for homogeneity (the Cochran’s Q test,
phet) and I-squared for the amount of heterogeneity in
parenthesis. DL pooled OR stands for the random effect model
derived from the DerSimonian-Laird estimator. MEC:
Multiethnic Cohort Study [7]; SEARCH: Studies of
Epidemiology and Risk Factors in Cancer Heredity [8]; NHS II:
Nurses’ Health Study (Han et al., 2009; premenopausal
women) [9]; NHS II: Nurses’ Health Study (Hunter et al., 2007;
postmenopausal women) [22]; Spain (Barroso et al., 2009)
[12]; Cyprus (Loizidou et al., 2010) [11]; SBCS: Sheffield
Breast Cancer Study.
(TIFF)
Figure S2.  Meta-analysis of the typed SNPs in the CHEK1
region. .  For each panel, fixed effect estimate (pooled OR) is
shown, with p value for homogeneity (the Cochran’s Q test,
phet) and I-squared for the amount of heterogeneity in
parenthesis. DL pooled OR stands for the random effect model
derived from the DerSimonian-Laird estimator. MEC:
Multiethnic Cohort Study [7]; SEARCH: Studies of
Epidemiology and Risk Factors in Cancer Heredity [8]; NHS II:
Nurses’ Health Study (Han et al., 2009; premenopausal
women) [9]; NHS II: Nurses’ Health Study (Hunter et al., 2007;
postmenopausal women) [22]; Cyprus (Loizidou et al., 2010)
[11]; SBCS: Sheffield Breast Cancer Study.
(TIFF)
File S1.  File S1.
(XLS)
Acknowledgements
We thank all the women who took part in this study. The
CGEMS breast cancer GWAS stage 1-NHS dataset was
ATR and CHEK1 SNPs with Breast Cancer
PLOS ONE | www.plosone.org 7 July 2013 | Volume 8 | Issue 7 | e68578
provided by the US National Institutes of Health (NIH) database
of Genotypes and Phenotypes (dbGAP, accession no.
phs000147.v1.p1). We thank the original investigators Hunter
DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE,
Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K,
Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg
CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ,
Hayes RB, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover
RN, Thomas G, and Chanock SJ for making the CGEMS data
available, and we acknowledge NIH funding for the NHS study,
as detailed in Hunter et al., [22].
Author Contributions
Conceived and designed the experiments: WYL AC. Performed
the experiments: RT JS. Analyzed the data: WYL AC.
Contributed reagents/materials/analysis tools: IWB DC HC
MWRR SPB LACA NJC. Wrote the manuscript: WYL AC.
References
1. Stratton MR, Rahman N (2008) The emerging landscape of breast
cancer susceptibility. Nat Genet 40: 17-22. doi:10.1038/ng.2007.53.
PubMed: 18163131.
2. Houlston RS, Webb E, Broderick P, Pittman AM, Di Bernardo MC et al.
(2008) Meta-analysis of genome-wide association data identifies four
new susceptibility loci for colorectal cancer. Nat Genet 40: 1426-1435.
doi:10.1038/ng.262. PubMed: 19011631.
3. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL et al. (2008)
Meta-analysis of genome-wide association data and large-scale
replication identifies additional susceptibility loci for type 2 diabetes. Nat
Genet 40: 638-645. doi:10.1038/ng.120. PubMed: 18372903.
4. Altshuler DL, Durbin RM, Abecasis GR, Bentley DR, Chakravarti A et
al. (2010) A map of human genome variation from population-scale
sequencing. Nature 467: 1061-1073. doi:10.1038/nature09534.
PubMed: 20981092.
5. Enders GH (2008) Expanded roles for Chk1 in genome maintenance. J
Biol Chem 283: 17749-17752. doi:10.1074/jbc.R800021200. PubMed:
18424430.
6. Yarden RI, Pardo-Reoyo S, Sgagias M, Cowan KH, Brody LC (2002)
BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon
DNA damage. Nat Genet 30: 285-289. doi:10.1038/ng837. PubMed:
11836499.
7. Haiman CA, Hsu C, de Bakker PI, Frasco M, Sheng X et al. (2008)
Comprehensive association testing of common genetic variation in
DNA repair pathway genes in relationship with breast cancer risk in
multiple populations. Hum Mol Genet 17: 825-834. PubMed: 18056155.
8. Pooley KA, Baynes C, Driver KE, Tyrer J, Azzato EM et al. (2008)
Common Single-Nucleotide Polymorphisms in DNA Double-Strand
Break Repair Genes and Breast Cancer Risk. Cancer Epidemiol
Biomarkers Prev 17: 3482-3489. doi:10.1158/1055-9965.EPI-08-0594.
PubMed: 19064565.
9. Han J, Haiman C, Niu T, Guo Q, Cox DG et al. (2009) Genetic variation
in DNA repair pathway genes and premenopausal breast cancer risk.
Breast Cancer Res Treat 115: 613-622. doi:10.1007/s10549-008-0089-
z. PubMed: 18551366.
10. Olson JE, Wang X, Pankratz VS, Fredericksen ZS, Vachon CM et al.
(2011) Centrosome-related genes, genetic variation, and risk of breast
cancer. Breast Cancer Res Treat 125: 221-228. doi:10.1007/
s10549-010-0950-8. PubMed: 20508983.
11. Loizidou MA, Cariolou MA, Neuhausen SL, Newbold RF, Bashiardes E
et al. (2010) Genetic variation in genes interacting with BRCA1/2 and
risk of breast cancer in the Cypriot population. Breast Cancer Res Treat
121: 147-156. doi:10.1007/s10549-009-0518-7. PubMed: 19714462.
12. Barroso E, Pita G, Arias JI, Menendez P, Zamora P et al. (2009) The
Fanconi anemia family of genes and its correlation with breast cancer
susceptibility and breast cancer features. Breast Cancer Res Treat 118:
655-660. doi:10.1007/s10549-009-0439-5. PubMed: 19536649.
13. Shephard ND, Abo R, Rigas SH, Frank B, Lin WY et al. (2009) A
Breast Cancer Risk Haplotype in the Caspase-8 Gene. Cancer Res 69:
2724-2728. doi:10.1158/0008-5472.CAN-08-4266. PubMed: 19318553.
14. Lin WY, Camp NJ, Cannon-Albright LA, Allen-Brady K,
Balasubramanian S et al. (2011) A role for XRCC2 gene
polymorphisms in breast cancer risk and survival. J Med Genet 48:
477-484. doi:10.1136/jmedgenet-2011-100018. PubMed: 21632523.
15. Allen-Brady K, Cannon-Albright LA, Neuhausen SL, Camp NJ (2006) A
role for XRCC4 in age at diagnosis and breast cancer risk. Cancer
Epidemiol Biomarkers Prev 15: 1306-1310. doi:
10.1158/1055-9965.EPI-05-0959. PubMed: 16835328.
16. Betel D, Wilson M, Gabow A, Marks DS, Sander C (2008) The
microRNA.org resource: targets and expression. Nucleic Acids Res 36:
D149-D153. doi:10.1093/nar/gkn293. PubMed: 18158296.
17. Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P et al. (2010)
Single-Nucleotide Polymorphisms Inside MicroRNA Target Sites
Influence Tumor Susceptibility. Cancer Res 70: 2789-2798. doi:
10.1158/1538-7445.AM10-2789. PubMed: 20332227.
18. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and
visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
doi:10.1093/bioinformatics/bth457. PubMed: 15297300.
19. Howie B, Marchini J, Stephens M (2011) Genotype imputation with
thousands of genomes. G3. Md: Bethesda 1: 457-470
20. Howie BN, Donnelly P, Marchini J (2009) A Flexible and Accurate
Genotype Imputation Method for the Next Generation of Genome-Wide
Association Studies. PLOS Genet 5: e1000529.
21. Yu W, Gwinn M, Clyne M, Yesupriya A, Khoury MJ (2008) A navigator
for human genome epidemiology. Nat Genet 40: 124-125. doi:10.1038/
ng0208-124. PubMed: 18227866.
22. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M et al. (2007) A
genome-wide association study identifies alleles in FGFR2 associated
with risk of sporadic postmenopausal breast cancer. Nat Genet 39:
870-874. doi:10.1038/ng2075. PubMed: 17529973.
23. Viechtbauer W (2010) Conducting Meta-Analyses in R with the metafor
Package. J Stat Softw 36: 1-48.
24. Sinha S, Singh RK, Bhattacharya N, Mukherjee N, Ghosh S et al.
(2011) Frequent alterations of LOH11CR2A, PIG8 and CHEK1 genes
at chromosomal 11q24.1-24.2 region in breast carcinoma: Clinical and
prognostic implications. Mol Oncol 5: 454-464. doi:10.1016/j.molonc.
2011.06.005. PubMed: 21803008.
ATR and CHEK1 SNPs with Breast Cancer
PLOS ONE | www.plosone.org 8 July 2013 | Volume 8 | Issue 7 | e68578
